Management of Metastatic Disease

What percentage of prostate cancer patients that you evaluate present for the first time with metastatic disease?

Do you use or have you used intermittent androgen suppression in the metastatic setting?

Generally, how many hormonal therapies or changes to hormonal therapies will you try before you consider a patient to have hormone-refractory disease?

Case 8: Asymptomatic metastatic disease — no prior therapy

Case 8: Asymptomatic metastatic disease — no prior therapy

Case 8: Asymptomatic metastatic disease — no prior therapy

Case 8: Asymptomatic metastatic disease — no prior therapy

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

In general, do you order CT scans, bone scans and MRIs for the following patients to rule out metastatic disease?

Which systemic therapy would you likely recommend to a 48-year-old patient presenting at first diagnosis with metastatic disease?

Which systemic therapy would you likely recommend to a 48-year-old patient presenting at first diagnosis with metastatic disease?

In general, do you recommend bisphosphonates to each of the following groups of patients?

In general, do you recommend bisphosphonates to each of the following groups of patients?

Case 9: Symptomatic metastatic disease

Case 9: Symptomatic metastatic disease

Case 9: Symptomatic metastatic disease

Case 9: Symptomatic metastatic disease

If you had prostate cancer, how likely would you be to receive chemotherapy if you were diagnosed with PSA-only relapse after local therapy and then progressed through hormone therapy with asymptomatic bone metastases?

If you had prostate cancer, how likely would you be to receive chemotherapy if you were diagnosed with PSA-only relapse after local therapy and then progressed through hormone therapy with asymptomatic bone metastases?

If you had prostate cancer, how likely would you be to receive chemotherapy if you were diagnosed with PSA-only relapse after local therapy and then progressed through hormone therapy with symptomatic bone metastases?

If you had prostate cancer, how likely would you be to receive chemotherapy if you were diagnosed with PSA-only relapse after local therapy and then progressed through hormone therapy with symptomatic bone metastases?

Do you believe that research on chemotherapy for metastatic prostate cancer has demonstrated a clinically significant favorable effect on survival?

Do you believe that research on chemotherapy for metastatic prostate cancer has demonstrated a clinically significant favorable effect on survival?

A >50% decrease in PSA from chemotherapy translates to improved survival in patients with androgen-independent metastatic prostate cancer.

A >50% decrease in PSA from chemotherapy translates to improved survival in patients with androgen-independent metastatic prostate cancer.

A 10% decrease in PSA from systemic therapy (either chemotherapy or hormonal therapy) may translate into improved survival in patients with androgen-independent metastatic prostate cancer.

A 10% decrease in PSA from systemic therapy (either chemotherapy or hormonal therapy) may translate into improved survival in patients with androgen-independent metastatic prostate cancer.

Chemotherapy for prostate cancer is more effective in 2006 than it was 10 years ago.

Chemotherapy for prostate cancer is more effective in 2006 than it was 10 years ago.

Chemotherapy for prostate cancer is better tolerated in 2006 than it was 10 years ago.

Chemotherapy for prostate cancer is better tolerated in 2006 than it was 10 years ago.

In general, all patients with metastatic prostate cancer should have a consultation with a medical oncologist at some point in the course of their decision-making or treatment.

In general, all patients with metastatic prostate cancer should have a consultation with a medical oncologist at some point in the course of their decision-making or treatment.

Docetaxel-based chemotherapy is generally well tolerated.

Docetaxel-based chemotherapy is generally well tolerated.

Docetaxel-based chemotherapy relieves bone pain from metastatic disease in about what percent of patients?

Docetaxel-based chemotherapy relieves bone pain from metastatic disease in about what percent of patients?

For a patient with hormone-refractory metastatic prostate cancer, generally how would you compare a docetaxel-based therapy with a mitoxantrone-based therapy in terms of efficacy in metastatic disease?

For a patient with hormone-refractory metastatic prostate cancer, generally how would you compare a docetaxel-based therapy with a mitoxantrone-based therapy in terms of efficacy in metastatic disease?

For a patient with hormone-refractory metastatic prostate cancer, generally how would you compare a docetaxel-based therapy with a mitoxantrone-based therapy in terms of safety and tolerability in metastatic disease?

For a patient with hormone-refractory metastatic prostate cancer, generally how would you compare a docetaxel-based therapy with a mitoxantrone-based therapy in terms of safety and tolerability in metastatic disease?

Imagine that 100 patients, all age 65, were to receive a docetaxel-based therapy. In your best estimate, what number of these patients who have docetaxel-based therapy side effects would fit into each of the following categories?

What percentage of your overall patient population with any stage of prostate cancer do you refer to a medical oncologist at any point?

What percentage of your overall patient population with metastatic prostate cancer do you refer to a medical oncologist at any point?

Of the patients with prostate cancer that you refer to a medical oncologist, approximately what percentage of the time is their prostate cancer?